| Literature DB >> 29867456 |
Xinyu Yang1,2, Nian Liu3, Xinye Li1,2, Yihan Yang1,2, Xiaofeng Wang2, Linling Li3, Le Jiang3, Yonghong Gao2, Hebin Tang4, Yong Tang5, Yanwei Xing1, Hongcai Shang2.
Abstract
Anthracyclines are effective agents generally used to treat solid-tumor and hematologic malignancies. The use of anthracyclines for over 40 years has improved cancer survival statistics. Nevertheless, the clinical utility of anthracyclines is limited by its dose-dependent cardiotoxicity that adversely affects 10-30% of patients. Anthracycline-induced cardiotoxicity may be classified as acute/subacute or chronic/late toxicity and leads to devastating adverse effects resulting in poor quality of life, morbidity, and premature mortality. Traditional Chinese medicine has a history of over 2,000 years, involving both unique theories and substantial experience. Several studies have investigated the potential of natural products to decrease the cardiotoxic effects of chemotherapeutic agents on healthy cells, without negatively affecting their antineoplastic activity. This article discusses the mechanism of anthracycline-induced cardiotoxicity, and summarizes traditional Chinese medicine treatment for anthracycline-induced heart failure (HF), cardiac arrhythmia, cardiomyopathy, and myocardial ischemia in recent years, in order to provide a reference for the clinical prevention and treatment of cardiac toxicity.Entities:
Keywords: adverse effects; anthracyclines; antineoplastic; cardiac toxicity; traditional Chinese medicine
Year: 2018 PMID: 29867456 PMCID: PMC5963334 DOI: 10.3389/fphar.2018.00444
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Mechanism involved in traditional Chinese medicine treated on cardiotoxicity induced by anthracycline. ROS, reactive oxygen species; EF, ejection fraction; FS, fractional shortening; LV flow, left ventricular outflow; LVDF, left ventricular diastolic function; LVEF, left ventricle ejection fraction; LVFS, left ventricular fractional shortening; LV mass, left ventricular mass; CK, creatine kinase; Tnl, troponin I; BNP, brain natriuretic peptide; CK-MB, creatine kinase isoenzymes; cTnT, cardiac Troponin T, Rg3, GinsenosideRg3; SA, Salvianolic acids; TSNIIA-SS, Tanshinone IIA sodium sulfonate; P. grandiflorum, Platycodon grandiflorum; GB, Ginkgolide B; ZGCT, Zhi Gan Cao Tang; XG, Xinfuli Granule; WXKL, Wenxin Granule; SYKT, Sanyang Xuedai; SMY, Sheng-Mai Yin; NOS, nitric oxide synthase; SND, Sini decoction; GU, Glycyrrhiza Uralensis; MDA, malondialdehyde; SC, Schisandra chinensis; SOD, superoxide dismutase.
Effect of traditional Chinese medicine on cardiotoxicity induced by anthracyclines.
| Heart failure | |||||
| Ginsenoside Rg3 (C42H72O13) | Adriamycin | Increased in the EF and FS, and improved the LV outflow. Activation of the Nrf2-ARE pathway and Akt pathway. | Wang et al., | ||
| Tanshinone IIA (C19H18O3) | Doxorubicin | Decreased the number of cleaved caspase-3 and cytosol cytochrome c, as well as increased BcL-xL expression. | Hong et al., | ||
| Vitexin (C21H20O10) | Doxorubicin | Increasing the expression levels of IL-1β, IL-6, NF-κB, and TNF-α, decrease caspase-3 activity, suppressed oxidative stress. | Sun et al., | ||
| Ginkgolide B (C20H24O10) | Doxorubicin | Decreased reactive oxygen species, and activating Akt phosphorylation, improved LVEF and reduced LV mass. | Gao et al., | ||
| Salvianolic acids | Doxorubicin | Improvement of ECG, and decline of CK. Blocked oxidative stress. | Jiang et al., | ||
| Xinmailong injection | Epirubicin | Activated the PI3K/Akt signaling pathway, suppressed the Erk1/2 and P38 MAPK signaling pathways. | Li et al., | ||
| Doxorubicin | Cleavage of caspases 9, 3, and 7 decreased. | Choi et al., | |||
| Anthracyclines | in clinic | Detection of ECG, LVDF, CK-MB, BNP, and TnI. | Hao et al., | ||
| Adriamycin | Nucleic acid and protein synthesis were suppressed, MDA was augmented, GSHPx activity and SOD were decreased. | You et al., | |||
| Doxorubicin | Increased in the levels of Bax, p53, phospho-p53, and Bcl-xL. | Li et al., | |||
| HuangQi injection and ShenMai injection | Anthracyclines | in clinic | Improvement of LVEF, and cTnI decreased. | Li et al., | |
| Sini decoction | Doxorubicin | Decreased SOD activity, augmented reactive oxygen species generation, increased MDA formation, decreased release of LDH, activating the PI3K/Akt signaling pathway. | Chen et al., | ||
| Zhi Gan Cao Tang | Anthracyclines | in clinic | The suppression of Na+/K+-ATPase. | Wu et al., | |
| Shenmai Yangxin Decoction | Anthracyclines | in clinic | Improvement of LVEF,and cardiac function. cTnl decreased. | Liang et al., | |
| Complement Qi and Activate Blood | Epirubicin | in clinic | Improvement of LVEF, left ventricular short shaft shorten rate and left ventricular end-diastolic diameter and end systolic diameter. | Yao et al., | |
| Xinfuli Granule | Doxorubicin | Improvement of LVEF and LVFS, lower expression of Bax, and higher expression of Bcl-2. | Lu et al., | ||
| Qiangxin Granules | Epirubicin | in clinic | BNP, cTNI, CK-MB decreased. Improvement of LVEF, and ECG. | Zhou and Wang, | |
| Qiliqiangxin capsule | Cisplatin | in clinic | CK-MB, and cTnT decreased. | Liu et al., | |
| Sanyang Xuedai | Doxorubicin | Inhibited reactive oxygen species-mediated apoptosis, increased CD34+/CD44+ cell counts, and CK-MB decreased. | Chen et al., | ||
| Sheng-Mai Yin | Doxorubicin | BNP, TGF-β1, and CK-MB decreased. The increase of HWI and LVMI. The inhibition of TLR2, MCP-1, INF-γ, and IL-6. | Ma et al., | ||
| Cardiac Arrhythmia | |||||
| Wenxin Granule | Anthracyclines | in clinic | CK, CK-MB, and cTnI decreased. | Lyu et al., | |
| Qifu Decoction | Adriamycin | Heart rate increased, QRS voltage increased and Q-T interval shortened, SOD and GSHPx strengthened, and the content of MDA decreased. | Yu et al., | ||
| Shenfu decoction | Adriamycin | Bcl-2 increased, Bax, Caspase-9, Caspase-3, and cytochrome C decreased. | Sun et al., | ||
| Baoxin Kang | Adriamycin | in clinic | SOD, MDA, and GSHPX decreased. | Sui et al., | |
| Cardiomyopathy | |||||
| Tanshinone IIA sodium sulfonate (C19H17NaO6S) | Doxorubicin | Decreasing ST-interval and QRS interval by ECG, increasing myocardial tensile strength using TTR assay. | Jiang et al., | ||
| Panax ginseng | Adriamycin | Bcl-2, Bax, cytc, Caspase-9 and Caspase-3 decreased. | Fan et al., | ||
| Mongholicus | |||||
| Zingiber officinale | |||||
| Aconitum carmichaeli | |||||
| Sini decoction | Doxorubicin | Partially adjusting the perturbed metabolic pathways. | Tan et al., |
TCM, traditional chinese medicine; ROS, reactive oxygen species; Nrf2-ARE, nuclear factor erythroid 2 related factor-antioxidant response element; EF, ejection fraction; FS, fractional shortening; LV flow, left ventricular outflow; ECG, electrocardiogram; LVDF, left ventricular diastolic function; CK-MB, creatine kinase isoenzymes; BNP, brain natriuretic peptide; TnI, troponin I; TNF-α, tumor necrosis factor-α; GSHPx, glutathione peroxidase; SOD, superoxide dismutase; MDA, malondialdehyde; LVFS, left ventricular fractional shortening; cTnI, cardiac troponin I; TTR, tension to rupture; cTNT, troponin T.